Wegovy HD 7.2mg: Who Qualifies for the Higher Dose and What the STEP UP Trial Shows
The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026 — a higher-dose version of the injectable GLP-1 medication Wegovy, designed for adults with obesity who have already tolerated the standard 2.4 mg dose for at least four weeks. In the pivotal STEP UP trial, the 7.2 mg weekly dose produced a 20.7% mean weight loss over 72 weeks, and more than a third of participants shed 25% or more of their body weight. If you are currently on Wegovy 2.4 mg and your weight loss has stalled, here is what you need to know about whether Wegovy HD may be an option for you.
What Is Wegovy HD and How Is It Different from Standard Wegovy?
Wegovy HD is a 7.2 mg weekly subcutaneous injection of semaglutide — the same active ingredient as the original Wegovy 2.4 mg, just at a three-times-higher dose. Novo Nordisk submitted the supplemental New Drug Application in November 2025, and the FDA cleared it under its National Priority Voucher pilot program in March 2026.
The standard titration schedule for Wegovy — starting at 0.25 mg and stepping up over several months to 2.4 mg — remains unchanged. Wegovy HD is not a starting dose. It is an additional maintenance option for patients who have completed titration to 2.4 mg, tolerated that dose for at least four weeks, and whose provider determines that further weight reduction is clinically indicated.
In practice, this means Wegovy HD is aimed at two groups:
- People who responded well to 2.4 mg but hit a weight-loss plateau and have not yet reached their goal weight.
- People with a higher starting BMI whose clinical response at 2.4 mg was modest.
Who Qualifies for Wegovy HD 7.2mg?
Under the current FDA-approved label, Wegovy HD is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight reduction and long-term maintenance in adults with:
- Obesity (BMI ≥ 30 kg/m²), or
- Overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.
The key eligibility requirement: you must have already tolerated semaglutide 2.4 mg for at least four weeks. Wegovy HD is not appropriate for semaglutide-naïve patients or those still in the initial titration phase.
Patients who would typically not qualify include:
- Those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — a contraindication shared with all GLP-1 receptor agonists.
- Patients who could not tolerate GI side effects at 2.4 mg (nausea, vomiting, gastroparesis), as higher doses tend to increase GI effects.
- People with active pancreatitis or a history of severe hypersensitivity to semaglutide.
Your provider will assess your complete medication list, comorbidities, and response history before recommending a dose increase.
What Did the STEP UP Trial Show?
The STEP UP program consisted of two parallel randomized Phase 3b trials published in The Lancet:
STEP UP (obesity without diabetes): 1,407 adults with obesity but without type 2 diabetes were randomized to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo for 72 weeks (following standard titration). Results at 72 weeks:
| Outcome | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
|---|---|---|---|
| Mean weight loss (efficacy) | 20.7% | 15.6% | 3.9% |
| Mean weight loss (intent-to-treat) | 18.7% | 13.9% | 3.7% |
| Achieved ≥ 25% weight loss | 33.2% | 16.7% | 0% |
| Achieved ≥ 20% weight loss | 51% | 30% | 1% |
| Dysesthesia (altered skin sensation) | 22% | 6% | 0.3% |
STEP UP T2D: A parallel trial in adults with obesity and type 2 diabetes showed similar superiority of the higher dose over 2.4 mg, with meaningful additional glycemic benefit.
The most notable new safety signal is dysesthesia — a tingling, burning, or altered sensation in the skin — which affected roughly one in five participants at 7.2 mg compared with about one in seventeen at 2.4 mg. This side effect is generally mild and often resolves over time, but it is something to discuss with your provider before titrating up.
Cardiovascular safety was consistent with the established GLP-1 class profile, and no new safety concerns were identified beyond the known GI effects (which were modestly higher at 7.2 mg) and the dysesthesia finding.
How Does Wegovy HD Compare to Other GLP-1 Options in 2026?
The GLP-1 landscape has expanded significantly in 2026. Here is how the main options compare for an adult with obesity without type 2 diabetes:
| Medication | Type | Approved max dose | Typical weight loss | Key differentiator |
|---|---|---|---|---|
| Wegovy HD (semaglutide) | Weekly injection | 7.2 mg | ~20.7% | Highest weight loss for semaglutide class |
| Wegovy (semaglutide) | Weekly injection | 2.4 mg | ~15.6% | Established 4+ year track record |
| Zepbound (tirzepatide) | Weekly injection | 15 mg | ~20–22% | GIP + GLP-1 dual agonist |
| Foundayo (orforglipron) | Daily oral pill | 36 mg | ~16% | Oral, no injection required |
| Wegovy Pill (oral semaglutide) | Daily oral pill | 50 mg | ~13–15% | Oral semaglutide, approved Dec 2025 |
Key considerations when choosing:
- Wegovy HD is specifically for people already established on semaglutide; it is not a first-line choice over Zepbound if you have not yet started a GLP-1.
- Tirzepatide (Zepbound) continues to show comparable or slightly higher weight loss than semaglutide at maximum doses, though head-to-head data comparing it to 7.2 mg semaglutide are not yet published.
- If injections are a barrier, Foundayo or the oral Wegovy pill offer pill-based alternatives, though with somewhat lower average weight loss.
What Side Effects Should You Expect at the Higher Dose?
Most of the side effect profile of Wegovy HD mirrors standard Wegovy, but at elevated rates:
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common. These are highest during initial titration and typically improve over several weeks. Eating smaller, lower-fat meals and staying hydrated reduces severity.
- Dysesthesia is the most notable new signal at 7.2 mg: roughly one in five patients reported abnormal skin sensations. In clinical trials, this was generally mild and transient.
- Injection-site reactions may occur but are uncommon.
- Rare but serious: GLP-1 medications carry class-wide precautions for thyroid C-cell tumors, pancreatitis, gallbladder disease, and hypoglycemia (especially in people also taking insulin or sulfonylureas). These risks apply at all doses.
The FDA label does not currently specify a minimum duration at 2.4 mg beyond four weeks before stepping up; your provider will use clinical judgment based on your response and tolerability.
How Can I Get Wegovy HD Through Telehealth?
Telehealth prescribers can evaluate and prescribe Wegovy HD as part of a supervised weight management program. A typical online visit will include:
- A review of your current weight, BMI, and comorbidities
- Confirmation that you have been on semaglutide 2.4 mg for at least four weeks and tolerated it
- Discussion of your weight-loss progress and remaining goals
- Assessment of any side effects or contraindications
- Prescription written if clinically appropriate, sent directly to a pharmacy
Pricing for Wegovy HD tracks closely with standard Wegovy. List price is approximately $1,300–$1,400 per month, though insurance coverage varies. Many commercial plans cover GLP-1 medications for obesity under the ACA’s preventive services expansion; Medicare Part D plans vary by formulary.
Learn more about supervised GLP-1 prescribing and weight management through Omnia TeleHealth at our telehealth weight loss service.
Frequently Asked Questions
Can I start Wegovy at the 7.2 mg dose? No. The FDA-approved label requires patients to have already tolerated semaglutide 2.4 mg for at least four weeks before stepping up to 7.2 mg. The standard Wegovy titration schedule (starting at 0.25 mg and increasing over several months) must be completed first.
Is Wegovy HD covered by insurance? Coverage depends on your specific plan. Many commercial insurance plans that cover Wegovy 2.4 mg will also cover Wegovy HD once the clinical criteria are met, but formulary placement and prior authorization requirements vary. A telehealth provider can help document medical necessity. Medicare Part D plans that cover weight-loss medications may also cover Wegovy HD; check your formulary or ask your plan directly.
Does Wegovy HD work better than Zepbound (tirzepatide)? No published head-to-head trial directly compares semaglutide 7.2 mg to tirzepatide 15 mg. Tirzepatide trials have shown mean weight losses of 20–22%, which overlaps with the 7.2 mg semaglutide STEP UP results. Both are strong options; the best choice depends on your history with either drug, tolerability, insurance coverage, and provider recommendation.
What is dysesthesia and is it dangerous? Dysesthesia is an altered skin sensation — often described as tingling, burning, itching, or numbness — that occurred in about 22% of participants in the STEP UP trial at the 7.2 mg dose, compared with 6% at 2.4 mg. In clinical trials, it was generally mild and often resolved without intervention. If you experience these sensations, report them to your provider; a dose reduction back to 2.4 mg typically resolves the symptom.
Can people with type 2 diabetes use Wegovy HD? Yes. The STEP UP T2D trial evaluated semaglutide 7.2 mg specifically in adults with both obesity and type 2 diabetes, showing meaningful additional weight loss and glycemic benefit. However, the primary FDA-approved GLP-1 medication for cardiovascular risk reduction in type 2 diabetes remains Mounjaro (tirzepatide, FDA approved August 2026) and Ozempic (semaglutide 1 mg, long-established). Your provider will help determine which GLP-1 is most appropriate given your full medical picture.
This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or adjusting any prescription medication. Individual results vary; typical outcomes from clinical trials may not apply to all patients.
Schedule a telehealth consultation with an Omnia TeleHealth provider to find out whether Wegovy HD is right for your weight management plan.